Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation

► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer.
► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis.
► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.